Systemic Sclerosis and Localized Scleroderma in Childhood
Section snippets
Juvenile systemic sclerosis
Juvenile systemic sclerosis (JSSc) is a chronic multisystemic connective tissue disease characterized by symmetrical thickening and hardening of the skin, associated with fibrous changes in internal organs. Although rare in children, it represents one of the most severe rheumatic conditions in pediatric rheumatology practice.
Juvenile localized scleroderma
JLS, also know as morphea, comprises a group of conditions that involve essentially the skin and subcutaneous tissues. They have various features and range from very small plaques to extensive fibrotic lesions that may cause significant functional and cosmetic deformity.
Although JLS is relatively uncommon, it is far more common than systemic sclerosis in childhood, by a ratio of at least 10:1 [20]. There is a mild female predilection (female to male ratio 2.4: 1) [21]. The mean age at disease
Summary
JLS is a challenging but uncommon disorder among children. A new classification is now available that recognizes that many children have more than one type of LS (morphea and linear) and that a small subset of patients have evidence of internal organ disease. New techniques are available to assess and follow lesions. Therapy is based on open-labeled experiences, and controlled trials using new guidelines are needed to determine the best approach to disease modification.
References (66)
- et al.
Congenital localized scleroderma
J Pediatr
(2006) - et al.
Subspecialty clinics: rheumatology and dermatology. Classification of morphea (localized scleroderma)
Mayo Clin Proc
(1995) - et al.
Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients
J Am Acad Dermatol
(2006) - et al.
Disabling pansclerotic morphea: clinical presentation in two adults
J Am Acad Dermatol
(2005) - et al.
Anticentromere antibody in localized scleroderma
J Am Acad Dermatol
(1986) - et al.
Topical calcipotriene for morphea/linear scleroderma
J Am Acad Dermatol
(1998) - et al.
Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized scleroderma and systemic scleroderma
J Am Acad Dermatol
(2000) - et al.
Photochemotherapy for systemic and localized scleroderma
J Am Acad Dermatol
(2000) - et al.
A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma
J Am Acad Dermatol
(2006) - et al.
The carcinogenic effect of UVA irradiation
J Invest Dermatol
(1983)